ASCVD Risk Factors Quick Reference
What ASCVD Means
Atherosclerotic cardiovascular disease (ASCVD) refers to conditions caused by plaque buildup in the arteries, including:
- Coronary artery disease (heart attack, angina)
- Cerebrovascular disease (stroke, TIA)
- Peripheral arterial disease
ASCVD risk reflects the likelihood of developing these conditions over time. Risk is determined by a combination of fixed traits, lifestyle factors, and medical conditions.
Major Non-Modifiable Risk Factors
Factor | Why It Matters |
|---|---|
Age | Risk rises steadily with advancing age |
Biological sex | Men develop ASCVD earlier; women’s risk rises after menopause |
Genetics / family history | ASCVD in first-degree male relative < 55 or female relative < 65 increases lifetime risk |
Ethnicity | Risk patterns differ across populations due to genetic, environmental, and healthcare access factors |
Major Modifiable Risk Factors
Factor | Mechanism |
|---|---|
High LDL-C / ApoB | Drives plaque formation in arterial walls |
Hypertension | Damages arteries and accelerates atherosclerosis |
Diabetes / elevated glucose | Promotes inflammation and vascular injury |
Smoking / nicotine exposure | Causes endothelial injury and clot risk |
Obesity / central adiposity | Worsens lipids, BP, and insulin resistance |
Physical inactivity | Contributes to metabolic and vascular dysfunction |
Metabolic Risk Cluster (Metabolic Syndrome Components)
Source: ATP III / AHA-NHLBI 2005
Component | Typical Threshold |
|---|---|
Abdominal obesity | Waist > 40 in (102 cm) men, > 35 in (88 cm) women |
Triglycerides | ≥ 150 mg/dL |
HDL-C | < 40 mg/dL (men), < 50 mg/dL (women) |
Blood pressure | ≥ 130/85 mmHg |
Fasting glucose | ≥ 100 mg/dL |
Presence of ≥ 3 components establishes diagnosis. Multiple components amplify cardiovascular risk beyond any single factor alone.
Additional Risk-Enhancing Factors
Source: 2019 ACC/AHA Primary Prevention Guideline
Factor | Relevance |
|---|---|
South Asian ancestry | Associated with higher ASCVD risk at given risk factor levels |
Lipoprotein(a) | Genetically driven LDL-like particle linked to early ASCVD |
Chronic kidney disease | Alters lipid metabolism and increases vascular calcification |
Chronic inflammatory disease | Accelerates plaque instability (e.g., rheumatoid arthritis, psoriasis, lupus, HIV) |
History of preeclampsia or gestational diabetes | Signals higher lifetime cardiovascular risk |
Premature menopause | Associated with increased ASCVD risk |
Elevated hs-CRP | Marker of vascular inflammation |
Lifestyle and Environmental Contributors
Factor | Impact |
|---|---|
Poor sleep | Increases BP, glucose, and appetite hormones |
Chronic stress | Raises sympathetic tone and inflammatory signaling |
Unhealthy diet patterns | Promote dyslipidemia and insulin resistance |
Excess alcohol | Elevates BP and triglycerides |
Air pollution | Linked to endothelial dysfunction and plaque progression |
How Risk Factors Combine
ASCVD risk is multiplicative, not additive. The coexistence of multiple factors (for example: smoking + diabetes + hypertension) increases risk more than any single factor alone. Risk assessment frameworks account for this clustering when estimating cardiovascular event probability.
10-Year Risk Categories
Source: 2019 ACC/AHA based on Pooled Cohort Equations
These categories describe how guidelines stratify risk; they do not replace individualized clinical decision-making.
Category | 10-Year Risk | Typical Guideline Approach |
|---|---|---|
Low | < 5% | Lifestyle focus |
Borderline | 5% to < 7.5% | Lifestyle; consider risk enhancers |
Intermediate | 7.5% to < 20% | Lifestyle + statin discussion |
High | ≥ 20% | Lifestyle + statin typically recommended |
Risk percentages estimate the probability of a heart attack, stroke, or cardiovascular death over the next 10 years. Your clinician interprets these numbers in the context of your full health picture.
ASCVD Risk Calculator
Estimate 10-year and lifetime risk: ASCVD Risk Estimator Plus (American College of Cardiology)
For adults ages 40–79 without existing cardiovascular disease.
Sources
- Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation.2019;140:
e596–e646. - Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal.2020;41:111–188.
- Grundy SM et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;
112:2735–2752.
- Arnett DK et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation.2019;140: